Get the Stockscreener App
236.28
2.98%
6.83
After Hours:
236.28
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $236.28, with a volume of 7.98M.
It is up +2.98% in the last 24 hours and up +2.11% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$229.45
Open:
$230.545
24h Volume:
7.98M
Relative Volume:
1.41
Market Cap:
$417.60B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
178.28
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
+1.69%
1M Performance:
+2.11%
6M Performance:
+29.97%
1Y Performance:
+37.59%
1-Day Range:
$230.14
$238.01
1-Week Range:
$228.00
$238.15
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
236.28 | 405.53B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,059.70 | 933.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.90 | 489.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
127.31 | 238.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.76 | 235.72B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
Top Research Reports for JPMorgan Chase, Netflix & AbbVie - Yahoo Finance
ABBV latest news: price expected to consolidate near highs — upside breakout may target $240 - Traders Union
Lip Augmentation Market to Witness Massive Growth by 2032 | - openPR.com
How AbbVie Inc. stock compares with tech leadersJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Unpacking the Latest Options Trading Trends in AbbVieAbbVie (NYSE:ABBV) - Benzinga
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressure - newser.com
The Escalator: AbbVie, Sonoma Biotherapeutics, Way Better Partners and more - Medical Marketing and Media
Is AbbVie Inc. (4AB) stock a buy before earnings resultsWeekly Stock Recap & Weekly Return Optimization Alerts - newser.com
How supply chain issues affect AbbVie Inc. stockPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Will AbbVie Inc. (4AB) stock profit from AI boomChart Signals & Reliable Price Action Trade Plans - newser.com
Why AbbVie Inc. stock appears on watchlistsMarket Performance Summary & Fast Moving Stock Watchlists - newser.com
How geopolitical risks impact AbbVie Inc. (Common Stock) (4AB0) stock2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Can AbbVie Inc. stock weather global recession2025 Price Momentum & Smart Money Movement Tracker - newser.com
Why AbbVie Inc. (4AB) stock stays resilientShare Buyback & Verified Entry Point Detection - newser.com
Is AbbVie Inc. stock undervalued at current priceJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Is AbbVie Inc. stock undervalued vs historical averagesTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionInflation Watch & Daily Oversold Bounce Ideas - newser.com
Can AbbVie Inc. stock sustain revenue growthDay Trade & Smart Allocation Stock Tips - newser.com
How reliable is AbbVie Inc. (4AB) stock dividend growthIPO Watch & Stepwise Entry and Exit Trade Signals - newser.com
Will AbbVie Inc. stock announce special dividendPortfolio Growth Summary & Weekly Top Gainers Trade List - newser.com
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulencePortfolio Update Report & High Yield Stock Recommendations - newser.com
AbbVie, Genmab's Epkinly gets FDA nod for pivotal lymphoma treatment - Crain's Chicago Business
Why Johnson & Johnson's Share Price Is Popping This Month - The Motley Fool
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
How AbbVie Inc. (4AB) stock benefits from digital adoptionQuarterly Profit Review & Free Expert Approved Momentum Trade Ideas - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominanceInflation Watch & Safe Entry Point Identification - newser.com
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell? - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Healthcare Rotation Underway: 3 Stocks Leading the Charge - MarketBeat
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3 - sharewise.com
Approvals extend use of Roche, AbbVie drugs in lymphoma - pharmaphorum
Will AbbVie Inc. stock outperform Dow Jones2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
Will AbbVie Inc. stock maintain strong growthJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
How higher bond yields impact AbbVie Inc. stock2025 Top Decliners & Weekly Top Gainers Alerts - newser.com
Glenmark 3.0 In The Making, Invigorated By IGI-AbbVie Deal - Citeline News & Insights
Is AbbVie Inc. reversing from oversold territoryQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
How AbbVie Inc. stock trades before earningsJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? - Yahoo Finance
AbbVie Gets FDA Approval for Epkinly Combo for Relapsed Follicular Lymphoma - MarketScreener
AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - Investing News Network
FDA approves AbbVie’s EPKINLY combination therapy for lymphoma By Investing.com - Investing.com Canada
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment - GuruFocus
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - WV News
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Tre - GuruFocus
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma - Seeking Alpha
Global drugmakers rush to boost US presence as tariff threat looms - Reuters
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast… - MarketScreener
How AbbVie Inc. stock performs in easing cycles2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):